The biotech firm discontinues its ReFocus-ALZ and ReThink-ALZ trials, marking a major shift in its neurodegenerative disease strategy.
The biotech firm discontinues its ReFocus-ALZ and ReThink-ALZ trials, marking a major shift in its neurodegenerative disease strategy.
New molecular imaging techniques show promise in improving cancer surgery precision and outcomes.
Arvinas and Pfizer’s vepdegestrant becomes the first oral PROTAC therapy approved for ER-positive breast cancer, opening new avenues …
New CMS rules signal a turning point for AI-powered cardiac diagnostics, paving the way for broader clinical adoption …
On November 13, 2024, the U.S. Food and Drug Administration (FDA) approved a novel gene therapy for aromatic …
Ocugen’s Gene Therapy Trials Light Up Times Square—New Data Offers Hope for Rare Retinal Diseases
With all three Phase 3 trials now enrolling, Akero Therapeutics is racing to bring its promising MASH therapy, …
Despite a muted IPO market and cautious M&A activity, biotech in 2024 proved that innovation never sleeps—especially when …
From schizophrenia to sleep apnoea, 2024 closes with landmark approvals that could redefine treatment standards across multiple therapeutic …
Exploring recent advancements in CRISPR therapies, personalized gene editing, and artificial intelligence transforming drug development and clinical trials.
Already a subscriber? Log in